{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:30:36Z","timestamp":1770496236289,"version":"3.49.0"},"reference-count":14,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n     Die radikale Zystektomie eignet sich nicht f\u00fcr jeden Patienten mit muskelinvasivem Urothelkarzinom der Harnblase. Obwohl die multimodale prim\u00e4r organerhaltende Therapie in der S3-Leitlinie zum Harnblasenkarzinom als Alternative aufgef\u00fchrt zur radikalen Zystektomie aufgef\u00fchrt wird, wird dieser Eingriff in Deutschland im Vergleich zu anderen L\u00e4ndern relativ selten durchgef\u00fchrt. In diesem Artikel wird versucht, die Verfahren miteinander zu vergleichen, um auf diese Art die Indikation genauer stellen zu k\u00f6nnen und die Praktiken innerhalb Deutschlands zu vereinheitlichen. Weiterhin wird auf die Rolle der Zystektomie im Rahmen moderner medikament\u00f6ser Therapiekonzepte eingegangen.\n    <\/jats:p>","DOI":"10.1055\/a-2586-5554","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T18:53:41Z","timestamp":1746471221000},"page":"340-343","source":"Crossref","is-referenced-by-count":1,"title":["Optionen des Blasenerhalts beim muskelinvasiven High-Risk-Urothelkarzinom der Harnblase"],"prefix":"10.1055","volume":"56","author":[{"given":"Oliver","family":"Hahn","sequence":"additional","affiliation":[{"name":"Urology and Pediatric Urology, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"K\u00fcbler","sequence":"additional","affiliation":[{"name":"Urology and Pediatric Urology, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"JA Witjes","year":"2024","journal-title":"European Urology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"Bladder Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines","volume":"22","author":"TW Flaig","year":"2024","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience","volume":"71","author":"NJ Giacalone","year":"2017","journal-title":"European Urology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ijrobp.2013.01.020","article-title":"Nomograms Predicting Response to Therapy and Outcomes After Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer","volume":"86","author":"JJ Coen","year":"2013","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience","volume":"61","author":"JA Efstathiou","year":"2012","journal-title":"European Urology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1111\/j.1464-410X.2010.09564.x","article-title":"Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer","volume":"107","author":"AM Maarouf","year":"2011","journal-title":"BJU International"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review","volume":"66","author":"G Ploussard","year":"2014","journal-title":"European Urology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3233\/BLC-160076","article-title":"The Role of Transurethral Resection in\u00a0Trimodal Therapy for Muscle-Invasive Bladder Cancer","volume":"2","author":"CM Russell","year":"2016","journal-title":"Bladder Cancer"},{"key":"ref10","first-page":"985","article-title":"15-Year Survival Rates after Transurethral Resection and Radiochemotherapy or Radiation in Bladder Cancer Treatment","volume":"31","author":"FS Krause","year":"2011","journal-title":"Anticancer Research"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"AR Zlotta","year":"2023","journal-title":"The Lancet Oncology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results","volume":"20","author":"C R\u00f6del","year":"2002","journal-title":"JCO"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"RH Mak","year":"2014","journal-title":"JCO"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/S0022-5347(17)39122-X","article-title":"Radical Radiotherapy for Muscle Invasive Transitional Cell Carcinoma of the Bladder: Failure Analysis","volume":"142","author":"MK Gospodarowicz","year":"1989","journal-title":"The Journal of Urology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00345-020-03436-0","article-title":"Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"39","author":"VM Schuettfort","year":"2021","journal-title":"World J Urol"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2586-5554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T23:12:15Z","timestamp":1753225935000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2586-5554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":14,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2025,7,22]]},"published-print":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2586-5554","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}